From political dialogue to practical collaboration: shaping the future of radiopharmacy

During his recent visit to the Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Saxony’s Minister for Economic Affairs, Dirk Panter, gained first-hand insights into how cutting-edge radiopharmaceutical research is paving the way for tomorrow’s cancer therapies.

The visit highlights what we strongly believe in at Hi-Acts: breakthrough innovation in radiopharmacy can only succeed when research, industry, clinics and policy work closely together – translating excellent science into real-world medical impact.

In our latest video, we show how Hi-Acts supports HZDR in building the nukliD network. By connecting outstanding research with industrial partners and clinical expertise, the initiative helps accelerate translation into medical applications:

With initiatives such as the Hi-Acts Tech-Lab Radionuclides, we help turn scientific excellence into impact. We do so by enabling access to infrastructure, fostering cross-sector collaboration and strengthening Saxony as a leading location for radiopharmacy and personalised cancer medicine.

Minister Panter’s visit underlines the importance of a strong and reliable innovation ecosystem – and a shared commitment to advancing radiopharmacy from the lab to the patient.

This is a strong example of how translation in radiopharmacy can succeed: close collaboration between research, industry, clinics and policy is the foundation for sustainable impact. Hi-Acts plays a key role in building powerful structures around nukliD, helping to position Saxony and Central Germany as a radiopharmacy hotspot with international visibility.

Watch the video: https://www.hi-acts.de/de/news/video-hi-acts-verbindet-wissenschaft-und-wirtschaft-mit-hzdr-und-der-hzdr-innovation-gmbh

Partners

Saxon State Ministry for Economic Affairs, Labour, Energy and Climate Protection; nukliD; Wirtschaftsförderung Sachsen GmbH; HZDR